Brittany Branch
Family · Laurinburg, NCNPI 1205486818
Payments from drug & device makers
Across 82 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$237
- AstraZeneca$173
- Novo Nordisk$124
- Lilly USA, LLC$115
- Exact Sciences$92
- Amgen$88
- plus $549 from 14 others
What the payments were for
- Food & beverage$1,35898%
- Education$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $237 |
| AstraZeneca | 11 | $173 |
| Novo Nordisk | 7 | $124 |
| Lilly USA, LLC | 8 | $115 |
| Exact Sciences | 5 | $92 |
| Amgen | 5 | $88 |
| Boehringer Ingelheim | 6 | $85 |
| Novartis | 4 | $77 |
| Bayer | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Merck | 2 | $28 |
| Dexcom, Inc. | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| GSK | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
How this compares
$1,379 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 59 | $48,214 |
| OzempicSemaglutide | 28 | $35,286 |
| TrulicityDulaglutide | 27 | $28,443 |
| JardianceEmpagliflozin | 23 | $22,217 |
| EliquisApixaban | 33 | $20,763 |
| LinzessLinaclotide | 18 | $18,098 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,441 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,178 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,150 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $1,429 |
| Fluticasone Propionate | 116 | $1,269 |
| Atorvastatin Calcium | 130 | $1,187 |
| Ventolin HfaAlbuterol Sulfate | 13 | $943 |
| Diclofenac Sodium | 20 | $855 |
| Gabapentin | 61 | $838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $173 | $48,21459 claims |
| Novo NordiskOzempic | $124 | $35,28628 claims |
| Lilly USA, LLCTrulicity | $115 | $28,44327 claims |
| Boehringer IngelheimJardiance | $85 | $22,21723 claims |
| AbbVieLinzess | $237 | $18,09818 claims |
| GSKBreo Ellipta, Incruse Ellipta | $15 | $13,61834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.
Other family in Laurinburg
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.